✦ LIBER ✦

P.145 Selection and persistence of occult minority genotype 2b hepatitis C infection in a patient treated with 48 weeks of pegylated interferon alpha-2b and ribavirin for genotype 5a

✍ Scribed by A.J. Buckton; R. Kulasegaram; S. Ngui; M. Fisher; R. James; S. Rangarajan; C. Teo

Book ID: 117770365
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 139 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80325-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Emergence of occult minority genotype 2b

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

✍ A.J. Buckton; R. Kulasegaram; S.L. Ngui; M. Fisher; R. James; S. Rangarajan; C.G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 362 KB

Short treatment (14 weeks) with pegylate

Short treatment (14 weeks) with pegylated interferon alpha-2B and ribavirin for the treatment of hepatitis C genotype 2/3 infection

✍ O. Dalgard; K. Skaug; S. Ritland; B. Myrvang; K. Hellum; K. Bjoro; H. Bell 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 307 KB

272 EARLY VIRAL RESPONSE OF CONTROLLED-R

272 EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL)

✍ E. Lawitz; Z. Younossi; P. Mehra; A. Rigney; Z. Krastev; K. Tchernev; D. Takov; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

610 IL-22, SFAS AND SFASL CONCENTRATION

610 IL-22, SFAS AND SFASL CONCENTRATION IN SERA OF HCV 1B GENOTYPE-INFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON ALPHA 2B AND RIBAVIRIN

✍ T.W. Lapinski; M.M. Dabrowska; J. Jaroszewicz; R. Flisiak 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated

733 Interim (week 12) phase 2b virologic

733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection

✍ S. Zeuzem; Y. Benhamou; D. Shouval; V. Bain; S. Pianko; R. Flisiak; M. Grigoresc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB